RecruitingPhase 2NCT05149768

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Principal Investigator
Janet E Pope, PhD
University of Western Ontario, Division of Rheumatology, St. Joseph's Health Care, London, Ontario, Canada
Intervention
Brentuximab vedotin(drug)
Enrollment
11 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Collaborators

Seattle Genetics (now a wholly owned subsidiary of Pfizer) · Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05149768 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials